IMP731
Ulcerative Colitis
About Immutep
Immutep is a clinical-stage biotech focused on harnessing the Lymphocyte Activation Gene-3 (LAG-3) pathway to modulate the immune system, with programs targeting both oncology and autoimmune diseases. Founded on the pioneering discovery of LAG-3 by its CSO, Dr. Frédéric Triebel, the company has built a diversified portfolio including first-in-class assets and out-licensed candidates. Its strategy combines internal development of lead programs like efti with strategic partnerships with companies such as Novartis, MSD, and Merck KGaA to accelerate clinical progress and maximize value.
View full company profileAbout Immutep
Immutep is a clinical-stage biotech focused on harnessing the Lymphocyte Activation Gene-3 (LAG-3) pathway to modulate the immune system, with programs targeting both oncology and autoimmune diseases. Founded on the pioneering discovery of LAG-3 by its CSO, Dr. Frédéric Triebel, the company has built a diversified portfolio including first-in-class assets and out-licensed candidates. Its strategy combines internal development of lead programs like efti with strategic partnerships with companies such as Novartis, MSD, and Merck KGaA to accelerate clinical progress and maximize value.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Mirikizumab | Eli Lilly | Phase 3 |
| Filgotinib | Gilead Sciences | Phase 3 |
| Obefazimod (ABX464) | Abivax | Phase 3 |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Phase 3 |
| DE-130 (Etrasimod) | Rohto Pharmaceutical | Phase 3 |
| DE-122 (Carotegrast methyl) | Rohto Pharmaceutical | Phase 3 |
| Methylene Blue MMX® | Cosmo Pharmaceuticals | Preclinical |
| KRP-203 (Amiselimod) | Kissei Pharmaceutical | Phase II |
| EVO301 | Evommune | Phase 1 |
| Pentasa (Mesalazine) | Zeria Pharmaceutical | Approved/Commercial |
| SER-301 | Seres Therapeutics | Phase 1b |
| SER-287 | Seres Therapeutics | Phase 2b |